Piramal Pharma begins Sevoflurane commercial production at Digwal facility

Mumbai: Piramal Pharma Limited has announced the commencement of commercial production of Sevoflurane at the Company’s facility located at Digwal, Telangana, India.

"This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the Company’s facility at Bethlehem, Pennsylvania, USA," the Company stated in a BSE filing.

This would boost the Company’s capability to also tap into Inhalation Anesthesia opportunities in the ROW markets in addition to the USA markets, as per Piramal.

Medical Dialogues team had earlier reported that BrePco Biopharma Limited (BPCO) that develops products for the unique needs of paediatric patients and Piramal Critical Care (PCC), a division of Piramal Pharma Limited had received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the use of Neoatricon - a paediatric strength solution for infusion of Dopamine Hydrochloride.

Read also: Piramal Critical Care launches Chlorpromazine Hydrochloride for Injection in US

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

Read also: Piramal Pharma appoints Sai Ramana Ponugoti as CEO, India Consumer Healthcare

PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies.

In addition, PPL has a joint venture with Allergan. In October 2020, the company received a growth equity investment from the Carlyle Group.

Read also: Piramal Pharma arm, BrePco Biopharma get UKMHRA approval for Neoatricon in UK